Pfizer, the pharmaceutical giant that has developed with the company BioNTech the anti-Covid with which vaccinations were started in Italy and in the rest of Europe, it could decide to send fewer supply vials to the various Member States. A hypothesis that is taking hold after the first administrations of the vaccine, when medical health professionals around the world realized that inside each bottle there are and cannot be used. 5 vaccine doses (as originally planned), but 6. And taking into account that the supplies purchased by the different states vary not in the number of vials, but in the number of doses, that sixth extra dose could make Pfizer decide, even net of the great production pressure, to reduce the number of vials to be delivered. from which to derive the following ones 6 doses.
A dosage already certified on 8 January by the Committee for Medicinal Products for Human Use of the EMA, the European Medicines Agency, which was followed by the indication of Aifa (Italian Medicines Agency) and the Ministry della Salute to proceed with the extraction of six doses for each vial of Pfizer vaccine. Also for this reason there are regions, like Campania, which compared to the forecasts calculated on 5 doses of vaccine for each bottle, using the 6 doses exceeded the administration of the first batch of supply going beyond the 100% of the delivered doses. However, there is an opposite risk: that of not being able to correctly use all six doses in the bottle, but only five, thus leaving a “bottom” that should be thrown away. In this sense, the EMA had in fact specified not to mix the “residues” of the doses between the various bottles to create new doses of vaccine, “scraping the bottom” of different vials.
Pfizer, for its part, could therefore decide either to send fewer vials to the various countries, including Italy, or to subsequently charge the extra doses sent to the various states. The second scenario, however, seems to be quite unlikely and a difficult way to go, but it remains a hypothesis on the table. Meanwhile, in Italy, with the arrival of the vaccine supplies of Modern and the hope that the green light will soon be given to the use of that of AstraZeneca, the confrontation between the Government and the Regions continues not only to take stock of the vaccination trend (which proceeds in scattered order and time among the various local realities), but to draw up the vaccination priority lists dividing the population into groups, also on the based on the supplies that are arriving and on the basis of the characteristics of each vaccine.